Statements (76)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
injection
|
| gptkbp:approves |
gptkb:2011
gptkb:FDA |
| gptkbp:atccode |
S01 LA05
|
| gptkbp:casnumber |
864223-12-0
|
| gptkbp:chemical_formula |
C_21 H_27 N_3 O_7 S
|
| gptkbp:clinical_trial |
gptkb:REVEAL_Study
gptkb:VEGF_Trap-Eye_Study Phase III CATT VIEW 1 VIEW 2 VISTA VIVID VIEW 1 Study VIEW 2 Study FAME Study REVEAL |
| gptkbp:clinical_use |
treatment of retinal diseases
|
| gptkbp:contraindication |
active ocular infection
uncontrolled systemic disease hypersensitivity to aflibercept |
| gptkbp:dosage_form |
solution for injection
|
| gptkbp:effective_date |
November 2011
|
| gptkbp:formulation |
solution for injection
sterile solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Eylea
|
| gptkbp:indication |
diabetic retinopathy
diabetic macular edema macular edema following retinal vein occlusion wet age-related macular degeneration |
| gptkbp:ingredients |
gptkb:aflibercept
|
| gptkbp:invention |
2028
patented |
| gptkbp:manufacturer |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:Japan gptkb:United_States gptkb:Eylea |
| gptkbp:mechanism_of_action |
VEGF inhibitor
|
| gptkbp:packaging |
single-use vial
|
| gptkbp:price |
varies by region
|
| gptkbp:provides_guidance_on |
gptkb:diabetes
gptkb:American_Academy_of_Ophthalmology gptkb:National_Eye_Institute |
| gptkbp:requires |
available online
|
| gptkbp:research_focus |
cost-effectiveness
patient adherence safety profile long-term efficacy comparative effectiveness |
| gptkbp:route_of_administration |
intravitreal injection
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
thromboembolic events
retinal detachment hypersensitivity eye pain vitreous floaters cataract increased intraocular pressure intraocular inflammation systemic effects ocular hemorrhage |
| gptkbp:storage |
refrigerated
|
| gptkbp:trade |
gptkb:Eylea
|
| gptkbp:used_for |
diabetic retinopathy
treatment of diabetic macular edema treatment of diabetic retinopathy treatment of retinal vein occlusion treatment of neovascular age-related macular degeneration |
| gptkbp:bfsParent |
gptkb:Regeneron_Pharmaceuticals
gptkb:Regeneron |
| gptkbp:bfsLayer |
4
|